JP2024543505A - 癌の治療方法 - Google Patents
癌の治療方法 Download PDFInfo
- Publication number
- JP2024543505A JP2024543505A JP2024529127A JP2024529127A JP2024543505A JP 2024543505 A JP2024543505 A JP 2024543505A JP 2024529127 A JP2024529127 A JP 2024529127A JP 2024529127 A JP2024529127 A JP 2024529127A JP 2024543505 A JP2024543505 A JP 2024543505A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- patients
- dose
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163264132P | 2021-11-16 | 2021-11-16 | |
| US63/264,132 | 2021-11-16 | ||
| PCT/GB2022/052903 WO2023089308A1 (en) | 2021-11-16 | 2022-11-16 | Methods for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024543505A true JP2024543505A (ja) | 2024-11-21 |
| JP2024543505A5 JP2024543505A5 (https=) | 2025-11-26 |
Family
ID=84535807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024529127A Pending JP2024543505A (ja) | 2021-11-16 | 2022-11-16 | 癌の治療方法 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4433025A1 (https=) |
| JP (1) | JP2024543505A (https=) |
| KR (1) | KR20240100420A (https=) |
| CN (1) | CN118475345A (https=) |
| AU (1) | AU2022390670A1 (https=) |
| CA (1) | CA3237681A1 (https=) |
| IL (1) | IL312680A (https=) |
| MX (1) | MX2024005855A (https=) |
| WO (1) | WO2023089308A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107148425B (zh) | 2014-10-29 | 2021-08-03 | 拜斯科阿迪有限公司 | 对mt1-mmp特异性的双环肽配体 |
| EP3645549A1 (en) | 2017-06-26 | 2020-05-06 | BicycleRD Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Cd137に対して特異的な二環式ペプチドリガンド |
| CN111902429A (zh) | 2018-02-23 | 2020-11-06 | 拜斯科技术开发有限公司 | 多聚体双环肽配体 |
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| WO2020128527A1 (en) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| US12492224B2 (en) | 2018-12-21 | 2025-12-09 | Bicycletx Limited | Bicyclic peptide ligands specific for PD-L1 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| AU2021322934A1 (en) | 2020-08-03 | 2023-03-30 | Bicycletx Limited | Peptide-based linkers |
| WO2025125648A1 (en) | 2023-12-13 | 2025-06-19 | Bicycletx Limited | Bicyclic peptide complex for use in treating cancer |
| WO2025125652A1 (en) * | 2023-12-13 | 2025-06-19 | Bicycletx Limited | Combination therapy for use in treating cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI860386B (zh) * | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
-
2022
- 2022-11-16 KR KR1020247019471A patent/KR20240100420A/ko active Pending
- 2022-11-16 CA CA3237681A patent/CA3237681A1/en active Pending
- 2022-11-16 WO PCT/GB2022/052903 patent/WO2023089308A1/en not_active Ceased
- 2022-11-16 EP EP22823612.1A patent/EP4433025A1/en active Pending
- 2022-11-16 IL IL312680A patent/IL312680A/en unknown
- 2022-11-16 CN CN202280086394.XA patent/CN118475345A/zh active Pending
- 2022-11-16 MX MX2024005855A patent/MX2024005855A/es unknown
- 2022-11-16 AU AU2022390670A patent/AU2022390670A1/en active Pending
- 2022-11-16 JP JP2024529127A patent/JP2024543505A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240100420A (ko) | 2024-07-01 |
| WO2023089308A1 (en) | 2023-05-25 |
| MX2024005855A (es) | 2024-05-28 |
| CA3237681A1 (en) | 2023-05-25 |
| EP4433025A1 (en) | 2024-09-25 |
| AU2022390670A1 (en) | 2024-05-23 |
| CN118475345A (zh) | 2024-08-09 |
| IL312680A (en) | 2024-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024543505A (ja) | 癌の治療方法 | |
| AU2020392890A1 (en) | Bicyclic peptide ligands specific for EphA2 and uses thereof | |
| AU2021276616A1 (en) | Bicyclic peptide ligands specific for Nectin-4 and uses thereof | |
| JP2024545125A (ja) | Stat3分解剤およびその使用 | |
| KR20250056270A (ko) | 활성화 fgfr3 유전자 변화를 갖는 고형 종양을 치료하는 방법 | |
| AU2024279019A1 (en) | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 AND USES THEREOF | |
| WO2024246547A1 (en) | Bicyclic peptide ligands specific for nectin-4 and uses thereof | |
| WO2024248859A1 (en) | Bicyclic peptide ligands specific for nectin-4 and uses thereof | |
| KR20250058748A (ko) | 중간엽 상피 전이 인자 (met)-표적 제제를 이용한 비-소 세포성 폐암 치료 방법 | |
| WO2025125648A1 (en) | Bicyclic peptide complex for use in treating cancer | |
| EP4427751A1 (en) | Pharmaceutical composition comprising pi3k and dna-pk dual inhibitor for preventing or treating peripheral t cell lymphoma | |
| WO2024248860A1 (en) | Bicyclic peptide ligands specific for epha2 and uses thereof | |
| WO2025056907A1 (en) | Bicyclic peptide ligands specific for nectin-4 and uses thereof | |
| EA047123B1 (ru) | Бициклические пептидные лиганды, специфические для нектина-4, и их применение | |
| WO2025260061A1 (en) | Compositions and methods for cancer therapy | |
| WO2025125809A1 (en) | Bicyclic peptide ligands specific for nectin-4 and uses thereof | |
| WO2024076633A1 (en) | Methods of treating estrogen receptor-mediated disorders | |
| KR20250069903A (ko) | 암 치료를 위한 B-Raf 저해제와 항-EGFR 항체의 조합물 | |
| WO2025125652A1 (en) | Combination therapy for use in treating cancer | |
| WO2025117875A1 (en) | Compounds for treating solid tumors having activating fgfr2 gene alterations | |
| EP4598520A1 (en) | Methods of treating estrogen receptor-mediated disorders | |
| CA3269490A1 (en) | Methods of treating estrogen receptor-mediated disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251114 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251114 |